The lenalidomide case Another case before the Competition Commission stems from a complaint that accuses the pharmaceutical company Celgene of overpricing the multiple myeloma medicine lenalidomide.

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Bristol-Myers faces a renewed $6.7 billion lawsuit, alleging delayed approval for drugs like Breyanzi, affecting contingent ...

Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene shareholders by ...

The global cellular reprogramming tools market is on an impressive growth trajectory, with a projected valuation of USD 400 ...

Cash balance at $18.5 millionStrengthened leadership team with new members driving stenoparib developmentNASDAQ compliance ...

NEW YORK (Reuters) - Bristol Myers Squibb was hit on Thursday with a $6.7 billion lawsuit claiming it cheated former Celgene ...

More recent acquisitions in 2024—oncology firms Mirati and RayzeBio and neurology firm Karuna—also help support Bristol's strong overall pipeline and wide moat. Bristol has created a strong pipeline ...

Celgene is closing in on yet another new indication for its blood cancer blockbuster Revlimid, with the FDA starting a priority review of the drug in combination with Roche’s Rituxan. If ...

Clinical data from the RESET-Myositis™ and RESET-SLE™ trials, along with initial clinical data from the RESET-SSc™ trial, to be presented this ...

Minimal residual disease (MRD) has emerged as a significant marker in the treatment of multiple myeloma (MM), allowing ...

Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, ...